The use of encainide in atrial fibrillation.
Based on its electrophysiologic characteristics, encainide, a new type 1 antiarrhythmic agent, was selected for a therapeutic trial in a case of refractory paroxysmal atrial fibrillation. This approach represents an attempt to manage the pathophysiologic disturbance of atrial fibrillation by selection of a drug that would be expected to have specific effects on the conduction system.
D000813:Anilides / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D016700:Encainide; D006801:Humans; D008297:Male; D014700:Verapamil / Q000627:therapeutic use*
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D014700:Verapamil; D016700:Encainide